Table 1 Baseline characteristics and demographics
PI-experienced, but SQV-naïve patients | n = 426 |
|---|---|
Male, % (n) | 84 (359) |
Age in years, median (IQR) | 43 (37; 49) |
Height in cm, median, (IQR) | 177 (172; 182) |
weight in kg, median (IQR) | 72 (65; 80) |
Hepatitis b, % (n) | 5 (21) |
Hepatitis c, % (n) | 12 (50) |
Infection mode, % | |
MSM | 62 |
Heterosexual | 15 |
IVDU | 7 |
Not specified | 16 |
Race, % | |
Caucasian | 84 |
African | 8 |
Asian | 3 |
Not specified | 5 |
CDC stage, % | |
A | 17 |
B | 43 |
C | 38 |
Not specified | 2 |
Time since first diagnosis in years, median (IQR) | 9 (4; 14) |
Time since first ART in years, median (IQR) | 7.3 (3.4; 9.4) |
Number of previous regimen, median (IQR) | 4 (3; ≥ 6) |
Number of previous PIs, median (IQR) | 2 (1; 3) |
Treatment interruption before start of new regimen, % (n) | 21 (91) |
Duration of treatment interruption in months, median (IQR) | 8.8 (3; 23) |
HIV RNA (copies/ml), median (IQR) | 599 (< 50; 31,291) |
Proportion of patients with HIV RNA < 50 copies/ml at baseline | 31.7% |
CD4-count (cells/mm3) median (IQR) | 320 (177; 506) |